Advaxis Jumps on Deal to Be Bought by Biosight

103
17
Favorite

Advaxis Jumps on Deal to Be Bought by Biosight

Thestreet2021-07-06

Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock. At closing, Biosight holders will own 75% of the company and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

103

Report

Comment（17）

Mm101
·2021-07-07
Like
Reply
2
Report
Fold Replies
- Mm101:
  Good
  2021-07-12
  Reply
  Report
Mm101
·2021-07-07
Yes
Reply
2
Report
Fold Replies
- Mm101:
  Nice
  2021-07-07
  Reply
  Report
Lyncia
·2021-07-07
[Anger]
Reply
3
Report
Newthk
·2021-07-07
Hi
Reply
Like
Report
cklcklckl
·2021-07-06
大家好
Reply
2
Report
Joyvb
·2021-07-06
why
Reply
1
Report
Joces
·2021-07-06
Please like and reply pls thx!
Reply
7
Report
Fold Replies
- Saltyninjazz:
  Ok
  2021-07-06
  Reply
  Report
mat4915
·2021-07-06
.
Reply
5
Report
Excelsheet
·2021-07-06
Comment like
Reply
9
Report
Fold Replies
- covfefebean:
  hok
  2021-07-06
  Reply
  Report
逢場作戲又一日
·2021-07-06
Great
Reply
9
Report
Fold Replies
- Bryansxr:
  .
  2021-07-06
  Reply
  Report
Joyvb
·2021-07-06
?
Reply
3
Report
Yh1
·2021-07-06
Hopping all go to the moon
Reply
4
Report
Maximus88
·2021-07-06
Oh
Reply
4
Report
Natmurali
·2021-07-06
Hmm
Reply
5
Report
WCH123
·2021-07-06
Ok
Reply
6
Report
Fold Replies
- ET_ML:
  Hi
  2021-07-06
  Reply
  Report
ET_ML
·2021-07-06
Like and comment please
Reply
4
Report
Fold Replies
- hamham611:
  Done
  2021-07-06
  Reply
  Report
- Jyen:
  Sure
  2021-07-06
  Reply
  Report
JHx
·2021-07-06
Hmm
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1118465420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-06 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118465420","market":"us","top_or_hot":-1,"title":"Advaxis Jumps on Deal to Be Bought by Biosight","media":"Thestreet","content":"<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADXS","symbol_name":"Ayala Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","article_id":"1118465420","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","pubTimestamp":1625580135,"sourceInfo":null,"weMediaInfo":null,"summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","collect":0,"end_time":0,"defaultTopTitle":"thestreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"translate_title":"Advaxis Inc.同意被Biosight收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADXS":0.9},"content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":140941483,"gmtCreate":1625625743542,"gmtModify":1703745183812,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3565081661382277","idStr":"3565081661382277"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140941483","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5193744,"gmtCreate":1626066495534,"gmtModify":1663230850938,"authorId":3565081661382277,"author":{"id":3565081661382277,"idStr":"3565081661382277","authorId":3565081661382277,"name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":140941483,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":140941587,"gmtCreate":1625625726249,"gmtModify":1703745182822,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3565081661382277","idStr":"3565081661382277"},"htmlText":"Yes&nbsp;","listText":"Yes&nbsp;","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140941587","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5145183,"gmtCreate":1625625735442,"gmtModify":1663230632746,"authorId":3565081661382277,"author":{"id":3565081661382277,"idStr":"3565081661382277","authorId":3565081661382277,"name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":140941587,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":157465225,"gmtCreate":1625611324267,"gmtModify":1703744723545,"author":{"id":"3573731744796242","authorId":"3573731744796242","name":"Lyncia","avatar":"https://static.tigerbbs.com/49f028b5d2bdd6033e8767d4ec0ff621","vip":1,"crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3573731744796242","idStr":"3573731744796242"},"htmlText":"[Anger]&nbsp;","listText":"[Anger]&nbsp;","text":"[Anger]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157465225","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157541866,"gmtCreate":1625595685155,"gmtModify":1703744624451,"author":{"id":"3577334382857440","authorId":"3577334382857440","name":"Newthk","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3577334382857440","idStr":"3577334382857440"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157541866","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157232913,"gmtCreate":1625582829232,"gmtModify":1703744402138,"author":{"id":"3582687913455140","authorId":"3582687913455140","name":"cklcklckl","avatar":"https://static.tigerbbs.com/b2ec6b6794830f516eea2c967e740df5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3582687913455140","idStr":"3582687913455140"},"htmlText":"大家好","listText":"大家好","text":"大家好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157232913","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":157206050,"gmtCreate":1625582181270,"gmtModify":1703744372048,"author":{"id":"3576137125360966","authorId":"3576137125360966","name":"Joyvb","avatar":"https://static.tigerbbs.com/7bf71cf06d5ef05352919f59d53ed5b4","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3576137125360966","idStr":"3576137125360966"},"htmlText":"why","listText":"why","text":"why","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157206050","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157642288,"gmtCreate":1625581566544,"gmtModify":1703744348126,"author":{"id":"4088507078206060","authorId":"4088507078206060","name":"Joces","avatar":"https://static.tigerbbs.com/fe1cc1049e3a5cdd7a9dd7910ab81066","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"4088507078206060","idStr":"4088507078206060"},"htmlText":"Please like and reply pls thx!","listText":"Please like and reply pls thx!","text":"Please like and reply pls thx!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/157642288","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5140569,"gmtCreate":1625585358598,"gmtModify":1663230607453,"authorId":3576456241160292,"author":{"id":3576456241160292,"idStr":"3576456241160292","authorId":3576456241160292,"name":"Saltyninjazz","avatar":"https://community-static.tradeup.com/news/b64b840095438253ee2a99edb133214c","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157642288,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":157646381,"gmtCreate":1625581536643,"gmtModify":1703744344357,"author":{"id":"3570541662042264","authorId":"3570541662042264","name":"mat4915","avatar":"https://static.tigerbbs.com/43445345056ca908c78ef01ab3f4289a","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3570541662042264","idStr":"3570541662042264"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157646381","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157629429,"gmtCreate":1625580877161,"gmtModify":1703744311545,"author":{"id":"3563191428086420","authorId":"3563191428086420","name":"Excelsheet","avatar":"https://static.tigerbbs.com/30a30f253a4cec57f0a4d67ec91c7847","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3563191428086420","idStr":"3563191428086420"},"htmlText":"Comment like","listText":"Comment like","text":"Comment like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/157629429","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5139406,"gmtCreate":1625580916450,"gmtModify":1663230601737,"authorId":3574818487395338,"author":{"id":3574818487395338,"idStr":"3574818487395338","authorId":3574818487395338,"name":"covfefebean","avatar":"https://static.tigerbbs.com/6daabccdd5d64fabc254e7329d1db3a9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157629429,"type":1,"supId":0,"prevId":0,"content":"<u>hok</u>","text":"<u>hok</u>","html":"<u>hok</u>"}],"langContent":"EN"},{"id":157661262,"gmtCreate":1625580629856,"gmtModify":1703744298473,"author":{"id":"3555043402922696","authorId":"3555043402922696","name":"逢場作戲又一日","avatar":"https://community-static.tradeup.com/news/6a5fbf2ceb7c7ee0399d41e6348dadf7","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3555043402922696","idStr":"3555043402922696"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/157661262","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5139411,"gmtCreate":1625580928675,"gmtModify":1663230602753,"authorId":3583926081588684,"author":{"id":3583926081588684,"idStr":"3583926081588684","authorId":3583926081588684,"name":"Bryansxr","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157661262,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."}],"langContent":"EN"},{"id":157660445,"gmtCreate":1625580564287,"gmtModify":1703744294542,"author":{"id":"3576137125360966","authorId":"3576137125360966","name":"Joyvb","avatar":"https://static.tigerbbs.com/7bf71cf06d5ef05352919f59d53ed5b4","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3576137125360966","idStr":"3576137125360966"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157660445","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157660550,"gmtCreate":1625580558370,"gmtModify":1703744294705,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"htmlText":"Hopping all go to the moon","listText":"Hopping all go to the moon","text":"Hopping all go to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157660550","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157682904,"gmtCreate":1625580434208,"gmtModify":1703744286988,"author":{"id":"3580265488164620","authorId":"3580265488164620","name":"Maximus88","avatar":"https://static.tigerbbs.com/86d19effbbdd9cc5898210cf7c326349","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3580265488164620","idStr":"3580265488164620"},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157682904","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157686718,"gmtCreate":1625580427734,"gmtModify":1703744286825,"author":{"id":"3576130121029356","authorId":"3576130121029356","name":"Natmurali","avatar":"https://static.tigerbbs.com/e8dc31417a56057814b4f4bb1a8e2fd3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3576130121029356","idStr":"3576130121029356"},"htmlText":"&nbsp;Hmm","listText":"&nbsp;Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157686718","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157686925,"gmtCreate":1625580392867,"gmtModify":1703744285030,"author":{"id":"3569470728297142","authorId":"3569470728297142","name":"WCH123","avatar":"https://community-static.tradeup.com/news/12fd1b5f9305634488c2592d6abff42d","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3569470728297142","idStr":"3569470728297142"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/157686925","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5139252,"gmtCreate":1625580424061,"gmtModify":1663230603149,"authorId":3583120269776489,"author":{"id":3583120269776489,"idStr":"3583120269776489","authorId":3583120269776489,"name":"ET_ML","avatar":"https://static.tigerbbs.com/b5cbb3ec11a5ab78633eea40593fb098","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157686925,"type":1,"supId":0,"prevId":0,"content":"<u>Hi</u>","text":"<u>Hi</u>","html":"<u>Hi</u>"}],"langContent":"EN"},{"id":157681752,"gmtCreate":1625580360076,"gmtModify":1703744283568,"author":{"id":"3583120269776489","authorId":"3583120269776489","name":"ET_ML","avatar":"https://static.tigerbbs.com/b5cbb3ec11a5ab78633eea40593fb098","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3583120269776489","idStr":"3583120269776489"},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/157681752","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5139355,"gmtCreate":1625580729318,"gmtModify":1663230603143,"authorId":3583317605009222,"author":{"id":3583317605009222,"idStr":"3583317605009222","authorId":3583317605009222,"name":"hamham611","avatar":"https://static.tigerbbs.com/93ec720f840e7ee30b356356ba620f72","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157681752,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5139318,"gmtCreate":1625580619754,"gmtModify":1635235840611,"authorId":3576135505707768,"author":{"id":3576135505707768,"idStr":"3576135505707768","authorId":3576135505707768,"name":"Jyen","avatar":"https://static.tigerbbs.com/26e6375f3ec665599c9d6faa652445e7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157681752,"type":1,"supId":0,"prevId":0,"content":"Sure","text":"Sure","html":"Sure"}],"langContent":"EN"},{"id":157680776,"gmtCreate":1625580295195,"gmtModify":1703744279343,"author":{"id":"3573821515865359","authorId":"3573821515865359","name":"JHx","avatar":"https://static.tigerbbs.com/54eb39bebd911124a59d7bf934977d25","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3573821515865359","idStr":"3573821515865359"},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157680776","repostId":1118465420,"repostType":4,"repost":{"id":"1118465420","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc."},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":103,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}